All Research on Biotech

Insight

Case Studies
Case Studies

Alexion Pharmaceuticals, Inc.: Focus on ultra-rare diseases as a revenue and profit driver

In 2007, Alexion gained marketing approval for Soliris, which has since become the world’s single most expensive orphan drug. This case study analyzes Alexion's success with Soliris, potential challenges, and how it is combatting these going forward.

Published By MarketLine
$495
Buy
Report
Report

The Orphan Drug Market Outlook to 2017

This report provides an analysis of the orphan drug market. It comprises brands that have gained US FDA orphan drug approval, as well as Phase III pipeline candidates that have gained an orphan drug designation from the FDA.

Published By Datamonitor
$2800
Buy
Report
Report

Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality

Datamonitor provides an overview of and profiles key hemophilia A and B pipeline products launching in the near future in the US and five major EU markets (France, Germany, Italy, Spain, and the UK).

Published By Datamonitor
$2800
Buy

View all Insight >>

Market Data

Databook
Databook

Company Financials: Sunesis Pharmaceuticals, Inc.

In-depth Company Financials with Key Ratios, and Revenue details by segments and geographies for the last five years download the attached datapack (.xls file)

Published By Datamonitor
$75
Buy

Profiles

Company Profile
Company Profile

InterMune, Inc.

InterMune (or 'the company') is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. The company primarily operates in the US, Canada and Europe. It is headquartered in Brisbane, California and employed 353 people as of December 31, 2013.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

UCB S.A.

UCB (or 'the company') is a global biopharmaceutical company focused on the discovery and development for people living with severe diseases of the immune system or of the central nervous system (CNS). It has operations in about 40 countries across Europe, North America and Asia Pacific. It is headquartered in Brussels, Belgium, and employed 8,732 people as of December 31, 2013.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

GTx, Inc.

GTx (or 'the company') is a biopharmaceutical company engaged in the development and commercialization of small molecules that target hormone pathways to treat cancer and cancer-related muscle wasting, cancer supportive care, and other serious medical conditions. The company operates in the US where it is headquartered in Memphis, Tennessee. GTx employed 32 people as on December 31, 2013.

Published By MarketLine
$175
Buy

View all Profiles >>

No help is available.